First experience of allogeneic haematopoietic stem cell transplantation in patients with mantle cell lymphoma with a mutation in the TP53 gene

Introduction. Mutations in the TP53 gene in patients with mantle cell lymphoma (MCL TP53+) are associated with a low response to intensive chemotherapy (CT) and adverse outcomes. Allogeneic haematopoietic stem cells transplantation (allo-HSCT) is a curative approach in MCL-TP53+ patients.

Aim. Efficacy and safety assessment of allo-HSCT in MCL-TP53+ patients.

Main findings. During 2016–2020, allo-HSCT in MCL TP53+ was performed in three patients. Two of them were grafted from HLA-identical unrelated donors, and one — from a haploidentical donor. Pre-transplant conditioning was “fludarabine + treosulfan + melphalan” in one case, and “fludarabine + busulfan” — in the other two. In three patients, leukocyte and platelet counts were recovered at days +18 and +20, +17 and +21, +19 and +16 after allo-HSCT, respectively. Acute graft-versushost disease (aGVHD) was observed in all patients (grade I — in 2 patients, grade IV — in 1 patient). One patient developed chronic GVHD (cGVHD) of moderate grade. All three patients exhibited complete remission and 100% donor chimerism in allo-HSCT follow-up of 6, 15 and 40 months, respectively.

1. Sandoval-Sus J., Sotomayor E.M., Shah B.D. Mantle cell lymphoma: Contemporary diagnostic and treatment perspectives in the age of personalized medicine. Hematol Oncol Stem Cell Ther. 2017; 10(3): 99–115. DOI: 10.1016/j.hemonc.2017.02.003.

2. Geisler C.H., Kolstad A., Laurell A. et al. Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur. Br J Haematol. 2012; 158(3) :355–62. DOI: 10.1111/j.1365-2141.2012.09174.x.

3. Eskelund C.W., Kolstad A., Jerkeman M. et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016; 175(3): 410–8. DOI: 10.1111/bjh.14241.

4. Dreyling M., Klapper W., Rule S. Blastoid and pleomorphic mantle cell lymphoma: Still a diagnostic and therapeutic challenge! Blood. 2018; 132(26): 2722–9. DOI: 10.1182/blood-2017-08-737502.

5. Eskelund C.W., Dahl C., Hansen J.W. et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017; 130(17): 1903–10. DOI: 10.1182/blood-2017-04-779736.

6. Young K.H., Leroy K., Møller M.B. et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: An international collaborative study. Blood. 2008; 112(8): 3088–98. DOI: 10.1182/blood-2008-01-129783.

7. Tam C.S., Anderson M.A., Pott C. et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018; 378(13): 1211–23. DOI: 10.1056/NEJMoa1715519.

8. Agarwal R., Dawson M.A., Dreyling M. et al. Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials. Leuk Lymphoma. 2018; 59(12): 2769–81. DOI: 10.1080/10428194.2018.1457148.

9. Lin R.J., Ho C., Hilden P.D. et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol. 2019; 184(6): 1006–10. DOI: 10.1111/bjh.15721.

10. Dietrich S., Dreger P., Hermine O. et al. Haploidentical stem cell transplantation for patients with lymphoma: a position statement from the Lymphoma Working Party-European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2019; 55(2): 317–24. DOI: 10.1038/s41409-019-0583-4.

11. Hoster E., Dreyling M., Klapper W. et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008; 111(2): 558–65. DOI: 10.1182/blood-2007-06-095331.

12. Vorobyev V.I., Lorie Y.Y., Kravchenko S.K. Treatment protocol for mantle lymphoma in patients under 65 years. Programmatic treatment of blood diseases. Moscow: Praktika, 2012; 619–40 (In Russian).

13. Koroleva D.A., Zvonkov E.E., Gabeeva N.G., et al. Research treatment protocol for mantle lymphoma in patients under 65 years. Diagnostic algorithms and treatment protocols for blood diseases. Moscow: Praktika, 2018, 2: 531–55 (In Russian).

14. Goyal R.K., Goyal M., Sankaranarayan K. Grading acute graft-versus-host disease: Time to reconsider. Pediatr Transplant. 2015; 19(3): 252–4. DOI: 10.1111/petr.12433.

15. Oken M.M., Creech R.H., Davis T.E. Toxicology and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649–55. DOI: 10.1097/00000421-198212000-00014.

16. Barrington S.F., Mikhaeel N.G., Kostakoglu L. et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014; 32(27): 3048–58. DOI: 10.1200/JCO.2013.53.5229.

17. Lee S.J. Classification systems for chronic graft-versus-host disease. Blood. 2017; 129(1): 30–7. DOI: 10.1182/blood-2016-07-686642.

18. Weisenburger D.D., Nathwani B.N., Diamond L.W. et al. Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases. Cancer. 1981; 48: 1415–25.

19. Howard O.M., Gribben J.G., Neuberg D.S. et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002; 20(5): 1288–94. DOI: 10.1200/JCO.20.5.1288.

20. Kumar A., Sha F., Toure A. et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019; DOI: 10.1038/s41408-019-0209-5.

21. Kröger N., Hoffknecht M., Krüger W. et al. Allogeneic bone marrow transplantation for lymphoma. Blood Rev. 2000; 14(1): 1–13. DOI: 10.1054/blre.1999.0125.

22. Khouri I.F., Lee M.S., Romaguera J. et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy. Ann Oncol. 1999; 10(11): 1293–9. DOI: 10.1023/A:1008380527502.

23. Khouri I.F., Lee M.S., Saliba R.M. et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol. 2003; 21(23): 4407–12. DOI: 10.1200/JCO.2003.05.501.

24. Robinson S.P., Goldstone A.H., Mackinnon S. et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Br J Haematol. 2000; 110(1): 12–7. DOI: 10.1046/j.1365-2141.2000.02075.x.

25. Tam C.S., Bassett R., Ledesma C. et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009; 113(18): 4144–52. DOI: 10.1182/blood-2008-10-184200.

26. Kharfan-Dabaja M.A., Reljic T., El-Asmar J. et al. Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: A systematic review. Futur Oncol. 2016; 12(22): 2631–42. DOI: 10.2217/fon-2016-0146.

27. Duarte R.F., Labopin M., Bader P. et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019; 54(10): 1525–52. DOI: 10.1038/s41409-019-0516-2.

28. Fenske T.S., Zhang M.J., Carreras J. et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: Analysis of transplantation timing and modality. J Clin Oncol. 2014; 32(4): 273–81. DOI: 10.1200/JCO.2013.49.2454.

29. Krüger W.H., Hirt C., Basara N. et al. Allogeneic stem cell transplantation for mantle cell lymphoma—Final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol. 2014; 93(9): 1587–97. DOI: 10.1007/s00277-014-2087-z.

30. Rule S., Cook G., Russell N.H. et al. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. Br J Haematol. 2019; 184(6): 999–1005. DOI: 10.1111/bjh.15723.

31. Sandoval-Sus J.D., Faramand R., Chavez J. et al. Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. Leuk Lymphoma. 2019; 60(2): 309–16. DOI: 10.1080/10428194.2018.1468894.

32. Lachance S., Molucon-Chabrot C., Busque L. et al. First line allogeneic stem cell transplantation in mantle cell lymphoma (MCL). Blood. 2009; 114: 3366. DOI: 10.1182/blood.v114.22.3366.3366.

33. Xu-Monette Z.Y., Jeffrey Medeiros L., Li Y. et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012; 119(16): 3668–83. DOI: 10.1182/blood-2011-11-366062.

34. Cortelazzo S., Ponzoni M. Mantle cell lymphoma. Oncol Hamatol. 2020; DOI: 10.1016/j.critrevonc.2020.103038.

35. Rule S., Dreyling M., Goy A. et al. Ibrutinib for the treatment of relapsed/ refractory mantle cell lymphoma: Extended 3.5-year follow up from a pooled analysis. Haematologica. 2019; 104(5): e211–4. DOI: 10.3324/haematol.2018.205229.

36. Dreyling M., Jurczak W., Jerkeman M. et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study. Lancet. 2016; 387(10020): 770–8. DOI: 10.1016/S0140-6736(15)00667-4.

37. Wang M., Jain P., Lee H.L. et al. Frontline treatment with ibrutinib plus rituximab (IR) followed by short course R-Hypercvad/MTX is extremely potent and safe in patients (age ≤ 65 years) with mantle cell lymphoma (MCL)—results of phaseII window-1 clinical trial. Blood. 2019, 134(Suppl. 1): 3987. DOI: 10.1182/blood-2019-126044.

38. Davids M.S., Roberts A.W., Seymour J.F. et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017; 35(8): 826–33. DOI: 10.1200/JCO.2016.70.4320.

39. Jelinek T., Mihalyova J., Kascak M. et al. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). Am J Hematol. 2019; 94(1): E35–7. DOI: 10.1002/ajh.25331.

40. Sun M., Zhang H. Therapeutic antibodies for mantle cell lymphoma: A brand-new era ahead. Heliyon. 2019; 5(3): e01297. DOI: 10.1016/j.heliyon.2019.e01297.

41. Wang M., Schuster S.J., Phillips T. et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017; 10(1): 1–8. DOI: 10.1186/s13045-017-0537-5.

42. Goy A., Sinha R., Williams M.E. et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013; 31(29): 3688–95. DOI: 10.1200/JCO.2013.49.2835.

43. Morabito F., Skafi M., Recchia A.G. et al. Lenalidomide for the treatment of mantle cell lymphoma. Expert Opin Pharmacother. 2019; 20(5): 487–94. DOI: 10.1080/14656566.2018.1561865.

44. Dreger P., Michallet M., Bosman P. et al. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transplant. 2019; 54(1): 44–52. DOI: 10.1038/s41409-018-0207-4.

45. Jerkeman M., Eskelund C.W., Hutchings M. et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018; 5(3): e109–16. DOI: 10.1016/S2352-3026(18)30018-8.

46. Ghosh N., Karmali R., Rocha V. et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: A center for international blood and marrow transplant research analysis. J Clin Oncol. 2016; 34(26): 3141–9. DOI: 10.1200/JCO.2015.66.3476.

47. Kanate A.S., Mussetti A., Kharfan-Dabaja M.A. et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLAmatched unrelated donors. Blood. 2016; 127(7): 938–47. DOI: 10.1182/blood-2015-09-671834.

48. De Philippis C., Mariotti J., Bouabdallah R. et al. Haploidentical allogeneic hematopoietic cell transplantation for mantle cell lymphoma using post-transplantation cyclophosphamide graft-versus-host disease prophylaxis. Blood. 2018; 132: 5748. DOI: 10.1182/blood-2018-99-117005.

49. Beà S., Valdés-Mas R., Navarro A. et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA. 2013; 110(45): 18250–5. DOI: 10.1073/pnas.1314608110.

50. Ferrero S., Rossi D., Rinaldi A. et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020; 105(6): 1604–12. DOI: 10.3324/haematol.2018.214056.